Sympathetic activation in heart failure: A target of therapeutic approaches

被引:2
|
作者
P. Schnabel
M. Böhm
机构
[1] Klinik III für Innere Medizin der Universität zu Köln,
[2] Joseph-Stelzmann-Str. 9,undefined
[3] D-50924 Köln,undefined
[4] Germany,undefined
来源
Zeitschrift für Kardiologie | 1999年 / 88卷 / Suppl 3期
关键词
Key words Heart failure – neuroendocrine activation – sympathetic nervous system – signal transduction;
D O I
10.1007/s003920050575
中图分类号
学科分类号
摘要
In heart failure, decreased cardiac output leads to a number of adaptive mechanisms. Among these, neuroendocrine activation including activation of the renin-angiotensin-aldosterone system, augmentation of vasopressin and endothelin release, and activation of the sympathetic nervous system occur. The increase of adrenergic drive is characterized by decreased baroreceptor sensitivity, increased plasma norepinephrine levels and cardiac norepinephrine spillover, and desensitization of postsynaptic β-adrenergic signal transduction. While increased sympathetic drive initially helps to maintain contractile performance of the damaged heart, the above changes chronically result in catecholamine refractoriness and are associated with a poor prognosis.
引用
收藏
页码:S005 / S011
相关论文
共 50 条
  • [31] Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation
    Despas, Fabien
    Detis, Nicolas
    Dumonteil, Nicolas
    Labrunee, Marc
    Bellon, Brigitte
    Franchitto, Nicolas
    Galinier, Michel
    Senard, Jean-Michel
    Pathak, Atul
    JOURNAL OF HYPERTENSION, 2009, 27 (09) : 1849 - 1854
  • [32] EXCESSIVE SYMPATHETIC ACTIVATION IN HEART FAILURE WITH CHRONIC RENAL FAILURE: ROLE OF CHEMOREFLEX ACTIVATION
    Despas, F.
    Detis, N.
    Franchitto, N.
    Galinier, M.
    Senard, J. M.
    Pathak, A.
    JOURNAL OF HYPERTENSION, 2009, 27 : S36 - S37
  • [33] Excessive Sympathetic Activation in Heart Failure With Chronic Renal Failure: Role of Chemoreflex Activation
    Despas, Fabien
    Detis, Nicolas
    Labrunee, Marc
    Franchitto, Nicolas
    Galinier, Michel
    Senard, Jean-Michel
    Pathak, Atul
    CIRCULATION, 2010, 122 (21)
  • [34] Morbid Obesity as a Therapeutic Target for Heart Failure
    Chonyang L. Albert
    Current Treatment Options in Cardiovascular Medicine, 2019, 21
  • [35] Endothelin in heart failure: A promising therapeutic target?
    Love, MP
    McMurray, JJV
    HEART, 1997, 77 (02) : 93 - 94
  • [36] Mitochondrial function as a therapeutic target in heart failure
    Brown, David A.
    Perry, Justin B.
    Allen, Mitchell E.
    Sabbah, Hani N.
    Stauffer, Brian L.
    Shaikh, Saame Raza
    Cleland, John G. F.
    Colucci, Wilson S.
    Butler, Javed
    Voors, Adriaan A.
    Anker, Stefan D.
    Pitt, Bertram
    Pieske, Burkert
    Filippatos, Gerasimos
    Greene, Stephen J.
    Gheorghiade, Mihai
    NATURE REVIEWS CARDIOLOGY, 2017, 14 (04) : 238 - 250
  • [37] Morbid Obesity as a Therapeutic Target for Heart Failure
    Albert, Chonyang L.
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2019, 21 (10)
  • [38] Worsening Heart Failure Challenges as a Therapeutic Target
    Tang, W. H. Wilson
    Grodin, Justin L.
    JACC-HEART FAILURE, 2015, 3 (05) : 404 - 407
  • [39] Phospholamban:: A promising therapeutic target in heart failure?
    Schmidt, AG
    Edes, I
    Kranias, EG
    CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (05) : 387 - 396
  • [40] Phospholamban: A Promising Therapeutic Target in Heart Failure?
    Albrecht G. Schmidt
    Istvan Edes
    Evangelia G. Kranias
    Cardiovascular Drugs and Therapy, 2001, 15 : 387 - 396